Cardiometabolic Renal Health Profile, Intensive Blood Pressure‐Lowering Treatment and Cognitive Dysfunction: A Post Hoc Analysis of the SPRINT Trial
Authors' conclusion
Intensive BP-lowering treatment tended to be associated with greater absolute risk reductions for MCI among participants with favourable cardiometabolic renal health profiles.
Study context
- Population
- SPRINT participants with complete baseline profile data (FPG, non-HDL cholesterol, eGFR, urine albumin-to-creatinine ratio, subclinical and clinical CVD history); mean age 67.8 years, 35.2% women
- Participants
- 8,162 participants
- Comparison
- Intensive vs standard blood pressure (BP)-lowering treatment, by cardiometabolic renal health profile tertile
- Primary endpoint
- Cognitive outcomes: probable dementia, mild cognitive impairment (MCI) and a composite of the two
Methodological detailsexploratory tertile-based analyses
- Exploratory tertile-based analyses
Primary result
As reported in the abstract
MCI, intensive BP-lowering treatment in favourable profile
FavourableAdjusted hazard ratio (95% CI)
Intensivevs standard BP-lowering treatment
0.64(0.48–0.86)
FavourableAdjusted ARD, % (95% CI)P value
Largest absolute risk difference; interaction on the ARD scale
−3.05(−4.85% to −1.24%)
P = 0.039for interactionSafety
- No interaction was observed for adverse events
Original publication
Cardiometabolic Renal Health Profile, Intensive Blood Pressure‐Lowering Treatment and Cognitive Dysfunction: A Post Hoc Analysis of the SPRINT Trial. Diabetes Obes Metab. Published 12 August 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →